Glibenclamide-pregnenolone derivative has greater hypoglycemic effects and biodistribution than glibenclamide-OH in alloxan-rats

Biomedical Papers

Volumn 156, Issue 2, 2012, Pages 122-127

  Figueroa Valverde, Lauro ^a   Diaz Cedillo, Francisco ^b   Lopez Ramos, Maria ^a   Garcia Cervera, Elodia ^a   Pool Gomez, Eduardo ^a   Cardena Arredondo, Carlos ^c   Ancona Leon, Graciela ^a  

^a UNIVERSIDAD AUTÓNOMA DE CAMPECHE   (Mexico)

^b INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

^c Centro Estatal de Oncologia   (Mexico)

Author keywords

Biodistribution; Glibenclamide; Glucose; Pregnenolone

Indexed keywords

ALLOXAN; ANTIDIABETIC AGENT; DRUG DERIVATIVE; GLIBENCLAMIDE; METFORMIN; PREGNENOLONE;

ANIMAL; ARTICLE; BLOOD; DRUG COMBINATION; EXPERIMENTAL DIABETES MELLITUS; FEMALE; GLUCOSE BLOOD LEVEL; METABOLISM; RAT; TISSUE DISTRIBUTION; WISTAR RAT;

ALLOXAN; ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DRUG COMBINATIONS; FEMALE; GLYBURIDE; HYPOGLYCEMIC AGENTS; METFORMIN; PREGNENOLONE; RATS; RATS, WISTAR; TISSUE DISTRIBUTION;

ANIMALIA; RATTUS;

EID: 84863994772     PISSN: 12138118     EISSN: 18047521     Source Type: Journal    
DOI: 10.5507/bp.2012.028     Document Type: Article

References (25)

1. Kelsey I, Wright P. The action of hypoglycaemic sulphonylureas on carbohydrate metabolism in the fasted rat. Br J Pharmacol Chemother 1957;12(3):350-5.
2. Cerasi E, Efendic S, Thornqvist C, Luft R. Effect of two sulphonylureas on the dose kinetics of glucose-induced insulin release in normal and diabetic subjects. Acta Endocrinol (Copenh) 1979;91(2):282-93.
3. Graal MB, Wolffenbuttel BH. The use of sulphonylureas in the elderly. Drugs Aging 1999;15(6):471-81.
4. Beck-Nielsen H, Pedersen O, Lindskov HO. Increased insulin sensitivity and cellular insulin binding in obese diabetics following treatment with glibenclamide. Acta Endocrinol (Copenh) 1979;90(3):451-62.
5. Chan J, Tomlinson B, Critchley J, Cockram C, Walden R. Metabolic and hemodynamic effects of metformin and glibenclamide in normotensive NIDDM patients. Diabetes Care 1993;16(7):1035-38.
6. Hoffmann J, Spengler M. Efficacy of 24-week monotherapy with ascarbose, glibenclamide, or placebo in NIDDM patients. The Essen Study. Diabetes Care 1994;17(6):561-6.
7. Asplund K, Wiholm B, Lithner F. Glibenclamide-associated hypoglycaemia: a report on 57 cases. Diabetologia 1983;24:412-17.
8. Ferner RE, Neil HA. Sulphonylureas and hypoglycaemia. Br Med J 1988;296:959-60.
9. Pearson JC, Antal EJ, Rachl GL, Gorsch HK, Craig WA, Albert KA, Welling PG. Pharmacokinetic disposition of 14C-glyburide in patients with varying renal function. Clin Pharmac Ther 1986;39:318-24.
10. Ferner RE, Chaplin S. The relationship between the pharmacokinetics and pharmacodynamics effects of oral hypoglycaemic drugs. ClinPharmacokin 1987;12:379-401.
11. Garrino M, Schmeer W, Nenquin M, Meissner H, Henquin J. Mechanism of the stimulation of insulin release in vitro by HB 699, a benzoic acid derivative similar to the non-sulphonylurea moiety of glibenclamide. Diabetologia 1985;28:697-703.
12. Holstein A, Plaschke A, Hammer C, Egberts E. Characteristics and time course of severe glimepiride-versus glibenclamide-induced hypoglycaemia. Eur J Clin Pharmacol 2003;59:91-7
13. Holstein A, Plaschke A, Egberts E. Lower incidence of severe hypoglycaemic in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes/Metabolism Res Rev 2001;17(6):467-73.
14. Balant L, Fabre J, Zahnd G. Comparison of the Pharmacokinetics of Glipizide and Glibenclamide in Man. Eur J Clin Pharmacol 1975;8:63-9.
15. Groop L, Wfihlin-Boll E, Groop R, Totterman K, Melander A, Tolppanen E, Fyhrqvist F. Pharmacokinetics and Metabolic Effects of Glibenclamide and Glipizide in Type2 Diabetics. Eur J Clin Pharmacol 1985;28:697-704.
16. Jayo M, Cisneros F. Guide for the Care and Use of Laboratory Animals, Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, National Academy Press Washington, D. C 1996.
17. Figueroa-Valverde L, Díaz-Cedillo F, García-Cervera. Synthesis of Glibenclamide-pregnenolone conjugate and its relationship with physicochemical descriptors log P, π, Rm, Vm, Pc and St. Asian J Chem 2011;23(9):3999-4002.
18. Figueroa-Valverde L, Díaz-Cedillo F, Camacho-Luis A, López-Ramos M, García-Cervera E. Design and Synthesis of Carbamazepine-Alkyne Conjugate as Antidiabetic Agent: Study of Chemical Descriptors (log P and π). Asian J Chem 2010;22(9):7057-64.
19. Kawashima K, Kuzuya T, Matsuda A. Radioimmunoassay of glibenclamide. Diabetes 1979;28(3):221-6.
20. Schneider S, Ueberberg S, Korobeynikov A, Schechinger W, Schwanstecher C, Schwanstecher M, Klein H, Schirrmacher E. Synthesis and evaluation of a glibenclamide glucose-conjugate: A potential new lead compound for substituted glibenclamide derivatives as islet imaging agents. Regulatory Peptides 2007;139(1-3):122-7.
21. Yoda R, Arube Y, Takata J, Nagata Y, Matsushima Y. Technetium-99m Complexes with Steroid-2-aminooxyethyliminodiaceticAcid Conjugates. Chem Pharm Bull 1999;47(3):413-6.
22. Yumisley A, Rivero A, Zayas F, Mesa N, Hernández I, León M. Formulación de 99M TC-Macroagregadosde albúmina para estudios de perfusión pulmonar. Nucleus 2009;45:19-25.
23. Szkudelski T. The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiol Res 2001:50:536-46.
24. Seedher N, Kanojia M. Mechanism of interaction of hypoglycemic agents glimepiride and glipizide with human serum albumin. Central Eur J Chem 2009;7(1):96-104.
25. Fu J, Gaetani S, Oveisi F, Verme J, Serrano A, Rodríguez F, Rosengarth A, Luecke H, Di Giacomo B, Tarzia G, Piomelli D. Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-α. Nature 2003;425:90-3.